Anish Suri Ph.D.
Net Worth
Last updated:
What is Anish Suri Ph.D. net worth?
The estimated net worth of Dr. Anish Suri Ph.D. is at least $5,075,360 as of 25 Aug 2023. He owns shares worth $109,880 as insider, has earned $879,650 from insider trading and has received compensation worth at least $4,085,830 in Cue Biopharma, Inc..
What is the salary of Anish Suri Ph.D.?
Dr. Anish Suri Ph.D. salary is $583,690 per year as Pres & Chief Scientific Officer in Cue Biopharma, Inc..
How old is Anish Suri Ph.D.?
Dr. Anish Suri Ph.D. is 51 years old, born in 1974.
What stocks does Anish Suri Ph.D. currently own?
As insider, Dr. Anish Suri Ph.D. owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Cue Biopharma, Inc. (CUE) | Pres & Chief Scientific Officer | 135,638 | $0.81 | $109,880 |
What does Cue Biopharma, Inc. do?
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Anish Suri Ph.D. insider trading
Cue Biopharma, Inc.
Dr. Anish Suri Ph.D. has made 6 insider trades between 2018-2023, according to the Form 4 filled with the SEC. Most recently he purchased 4,000 units of CUE stock worth $11,040 on 25 Aug 2023.
The largest trade he's ever made was exercising 33,334 units of CUE stock on 3 Oct 2021. As of 25 Aug 2023 he still owns at least 135,638 units of CUE stock.
Cue Biopharma key executives
Cue Biopharma, Inc. executives and other stock owners filed with the SEC:
- Dr. Anish Suri Ph.D. (51) Pres & Chief Scientific Officer
- Mr. Daniel R. Passeri M.Sc., MSc., J.D. (64) Chief Executive Officer & Director
- Ms. Kerri-Ann Millar (55) Chief Financial Officer